Sökning: WFRF:(Kraak Robin P) > Bioresorbable Scaff...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04407naa a2200481 4500 | |
001 | oai:DiVA.org:uu-342873 | |
003 | SwePub | |
008 | 180223s2017 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3428732 URI |
024 | 7 | a https://doi.org/10.1056/NEJMoa16149542 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Wykrzykowska, Joanna J4 aut |
245 | 1 0 | a Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. |
264 | 1 | c 2017 |
338 | a print2 rdacarrier | |
500 | a Collaborator Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. | |
520 | a BACKGROUND: Bioresorbable vascular scaffolds were developed to overcome the shortcomings of drug-eluting stents in percutaneous coronary intervention (PCI). We performed an investigator-initiated, randomized trial to compare an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in the context of routine clinical practice.METHODS: We randomly assigned 1845 patients undergoing PCI to receive either a bioresorbable vascular scaffold (924 patients) or a metallic stent (921 patients). The primary end point was target-vessel failure (a composite of cardiac death, target-vessel myocardial infarction, or target-vessel revascularization). The data and safety monitoring board recommended early reporting of the study results because of safety concerns. This report provides descriptive information on end-point events.RESULTS: The median follow-up was 707 days. Target-vessel failure occurred in 105 patients in the scaffold group and in 94 patients in the stent group (2-year cumulative event rates, 11.7% and 10.7%, respectively; hazard ratio, 1.12; 95% confidence interval [CI], 0.85 to 1.48; P=0.43); event rates were based on Kaplan-Meier estimates in time-to-event analyses. Cardiac death occurred in 18 patients in the scaffold group and in 23 patients in the stent group (2-year cumulative event rates, 2.0% and 2.7%, respectively), target-vessel myocardial infarction occurred in 48 patients in the scaffold group and in 30 patients in the stent group (2-year cumulative event rates, 5.5% and 3.2%), and target-vessel revascularization occurred in 76 patients in the scaffold group and in 65 patients in the stent group (2-year cumulative event rates, 8.7% and 7.5%). Definite or probable device thrombosis occurred in 31 patients in the scaffold group as compared with 8 patients in the stent group (2-year cumulative event rates, 3.5% vs. 0.9%; hazard ratio, 3.87; 95% CI, 1.78 to 8.42; P<0.001).CONCLUSIONS: In this preliminary report of a trial involving patients undergoing PCI, there was no significant difference in the rate of target-vessel failure between the patients who received a bioresorbable scaffold and the patients who received a metallic stent. The bioresorbable scaffold was associated with a higher incidence of device thrombosis than the metallic stent through 2 years of follow-up. (Funded by Abbott Vascular; AIDA ClinicalTrials.gov number, NCT01858077 .). | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
700 | 1 | a Kraak, Robin P4 aut |
700 | 1 | a Hofma, Sjoerd H4 aut |
700 | 1 | a van der Schaaf, Rene J4 aut |
700 | 1 | a Arkenbout, E Karin4 aut |
700 | 1 | a IJsselmuiden, Alexander J4 aut |
700 | 1 | a Elias, Joëlle4 aut |
700 | 1 | a van Dongen, Ivo M4 aut |
700 | 1 | a Tijssen, Ruben Y G4 aut |
700 | 1 | a Koch, Karel T4 aut |
700 | 1 | a Baan, Jan4 aut |
700 | 1 | a Vis, M Marije4 aut |
700 | 1 | a de Winter, Robbert J4 aut |
700 | 1 | a Piek, Jan J4 aut |
700 | 1 | a Tijssen, Jan G P4 aut |
700 | 1 | a Henriques, Jose P S4 aut |
700 | 1 | a James, Stefanu Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR)0 (Swepub:uu)stjam367 |
710 | 2 | a Uppsala universitetb Institutionen för medicinska vetenskaper4 org |
773 | 0 | t New England Journal of Medicineg 376:24, s. 2319-2328q 376:24<2319-2328x 0028-4793x 1533-4406 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-342873 |
856 | 4 8 | u https://doi.org/10.1056/NEJMoa1614954 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.